Logo Logo
Hilfe
Hilfe
Switch Language to English

Dietlmeier, Sebastian; Ye, Yao; Kuhn, Christina; Vattai, Aurelia; Vilsmaier, Theresa; Schröder, Lennard; Kost, Bernd P.; Gallwas, Julia; Jeschke, Udo; Mahner, Sven und Heidegger, Helene Hildegard (2020): The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases. In: Scientific Reports, Bd. 10, Nr. 1, 1154 [PDF, 1MB]

Abstract

Recently our study identified EP3 receptor and galectin-3 as prognosticators of cervical cancer. The aim of the present study was the analysis of EP2 as a novel marker and its association to EP3, galectin-3, clinical pathological parameters and the overall survival rate of cervical cancer patients. Cervical cancer tissues (n = 250), as also used in our previous study, were stained with anti-EP2 antibodies employing a standardized immunohistochemistry protocol. Staining results were analyzed by the IRS scores and evaluated for its association with clinical-pathological parameters. H-test of EP2 percent-score showed significantly different expression in FIGO I-IV stages and tumor stages. Kaplan-Meier survival analyses indicated that EP3-negative/EP2-high staining patients (EP2 IRS score >= 2) had a significantly higher survival rate than the EP3-negative/EP2-low staining cases (p = 0.049). In the subgroup of high galectin-3 expressing patients, the group with high EP2 levels (IRS >= 2) had significantly better survival rates compared to EP2-low expressing group (IRS <2, p = 0.044). We demonstrated that the EP2 receptor is a prognostic factor for the overall survival in the subgroup of negative EP3 and high galectin-3 expressed cervical cancer patients. EP2 in combination with EP3 or galectin-3 might act as prognostic indicators of cervical cancer. EP2, EP3, and galectin-3 could be targeted for clinical diagnosis or endocrine treatment in cervical cancer patients, which demands future investigations.

Dokument bearbeiten Dokument bearbeiten